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By preventing urogenital schistosomiasis in
sexually active females through simple and
low-cost methods, we have an innovative
and timely opportunity to reduce and
possibly interrupt HIV/AIDS transmis-
sion throughout many rural areas of sub-
Saharan Africa.
More than 90% of the world’s 207
million cases of schistosomiasis occur in
sub-Saharan Africa [1], making this condi-
tion (as well as hookworm infection) one of
the most common neglected tropical dis-
eases in the region [1,2]. Based on
additional information that schistosomiasis
causes chronic anemia and inflammation
associated with severe disability among
children, adolescents, and young adults,
the disease burden resulting from schisto-
some infections in Africa may actually rival
better known conditions such as HIV/
AIDS, tuberculosis, and malaria [1,3].
Approximately two-thirds of the cases of
schistosomiasis in sub-Saharan Africa re-
sult from urinary tract infections caused by
Schistosoma haematobium. Shown in Figure 1
is a map of the geographic distribution of
urinary schistosomiasis in Africa, in which
the major foci of infection occur in
southeastern Africa, i.e., Kenya, Malawi,
Mozambique, Tanzania, Zimbabwe,
South Africa, and Zambia; in West Africa,
i.e., Burkina Faso, Mali, Niger, and
Nigeria; and in Angola and Sudan.
However, urinary schistosomiasis has been
almost eliminated from Egypt [4]. Of the
estimated 112 million cases of S. haemato-
bium infection in sub-Saharan Africa,
approximately 70 million are associated
with hematuria, 18 million with major
bladder wall pathology, and 9.6 million
with major hydronephrosis leading to
severe kidney damage [5]. The results
from Egypt suggest that these consequenc-
es may be avoidable provided that regular
praziquantel treatment reaches school-age
children at risk.
In addition, there is yet another and
largely hidden condition associated with
chronic S. haematobium infection. Studies
from the S. haematobium–endemic areas of
sub-Saharan Africa indicate that between
33% and 75% of infected women also
suffer from female genital schistosomiasis
(FGS) of the lower genital tract [6]. FGS
results from deposition of the schistosome
eggs in the uterus, cervix, vagina, or vulva,
and the ensuing host inflammation is
comprised of granulomas, fibrosis, and
angiogenesis (pathological localized blood
vessel formation) [6,7]. The cervix and the
vagina are the most common sites of egg
deposition, although post-mortem studies
have revealed that the upper genital tract is
also frequently involved [8]. FGS was
identified as an established clinical feature
of S. haematobium infection in Africa begin-
ning in the 1950s and early 1970s [8,9], but
it is only within the last two decades that its
full clinical spectrum has been revealed
[6,7,10–12]. The pathognomonic lesions
associated with S. haematobium infection in
the female genitals are mucosal grainy
sandy patches linked to egg granulomas,
which are usually associated with mucosal
bleeding (especially ‘‘contact bleeding’’
during pelvic examination or sexual inter-
course) and abnormal blood vessels [7].
The homogenous yellow sandy patches of
FGS may mimic the sexually transmitted
diseases (STDs) and have been found to be
associated with a variety of important
clinical manifestations including bleeding
disorders, dyspareunia, pelvic and lower
abdominal pain, vaginal discharge, pollaki-
suria, stress incontinence, and infertility
[6,7,11,12].
Now there is new evidence indicating
that the sandy patches of FGS increase
susceptibility to HIV/AIDS [13–15].
Schistosomiasis occurs predominantly in
rural areas, and although HIV/AIDS is
often considered an urban or semi-urban
infection, there are also important and
emerging foci of epidemic AIDS in
African rural communities [16]. A cross-
sectional study from a rural Zimbabwean
community reveals that women aged 20 to
49 with FGS exhibit a 3-fold risk of having
HIV relative to women without FGS [14].
Presumably, the schistosome egg granulo-
mas produce genital lesions and mucosal
barrier breakdown to facilitate HIV viral
entry in a manner similar to that described
for STDs such as viral infection from
herpes simplex virus 2 or human papillo-
mavirus, or syphilis [6,16–19]. Alterna-
tively, contact bleeding could promote
direct entry of HIV into the bloodstream,
or the CD4+ cells present in schistosome
egg granulomas could provide a nidus for
HIV viral entry and replication [6].
Regardless of the mechanism, it is
important to establish whether anti-schis-
tosomal treatment could represent an
innovative HIV/AIDS prevention strate-
gy. Towards this end, praziquantel is both
a highly effective and low-cost anti-schis-
tosomal therapy and a prophylactic agent
against schistosomal morbidity in adults.
The London-based Schistosomiasis Con-
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with ministries of health to conduct
appropriate national control programs
for schistosomiasis and other helminth
infections [20]. In Burkina Faso, SCI has
shown that when provided as a single mass
treatment in Burkina Faso praziquantel
can reduce the prevalence of S. haematobium
infection by 84% among girls and 78%
overall for at least 2 years [21–22]. SCI
has also demonstrated similar successes in
the other seven sub-Saharan African
countries where it operates [20]. SCI is
currently developing country-specific strat-
egies based on annual or biannual treat-
ment of school-age children according to
collected epidemiological evidence of
prevalence and intensity of infections,
and based on the World Health Organi-
zation (WHO) recommendations [23].
The WHO strategy is of mass drug
administration (MDA) with praziquantel
for all school-age children (enrolled and
not enrolled) once every 2 years in
moderate risk communities where the
prevalence of schistosomiasis exceeds
10%, and annually where the prevalence
exceeds 50% [24]. Among women with
FGS, praziquantel will result in parasito-
logical cure and halt the appearance of
new ova in the urine and presumably in
the genital tract [25]. However, while
there are instances when treatment will
also reverse some of the lower genital tract
abnormalities associated with FGS [26],
regrettably praziquantel anthelminthic
therapy among adult women (with estab-
lished genital schistosomiasis) does not
alleviate genital lesions, contact bleeding,
or vessel abnormalities [25]. Therefore,
based on the presumed mechanism by
which FGS promotes HIV infection, it is
unlikely that praziquantel treatment of
affected adults will interrupt the horizontal
transmission of HIV/AIDS.
Our hypothesis is that treatment of
younger females at risk of schistosomiasis
is therefore critical, and that praziquantel
treatment of young school-age girls will
prevent the development of FGS and
therefore represent an innovative AIDS
prevention strategy in areas of HIV and S.
haematobium transmission. In a cross-sec-
tional study in northern Zimbabwe, wom-
en who report having received praziquan-
tel treatment before the age of 20
exhibited an absence of sandy patches
and contact bleeding that was independent
of adult waterbody contact [27]. Based on
this study, we believe there is an urgent
need to demonstrate the impact of praz-
iquantel on HIV transmission in prospec-
tive studies among school-age girls living
in HIV/AIDS and schistosomiasis co-
endemic areas, such as in the southeastern
countries of Malawi, Mozambique, Tan-
zania, and Zimbabwe, areas which exhibit
high prevalences of both S. haematobium
and HIV infections (Figures 1 and 2). We
further support efforts to seek additional
funds in order to investigate this innova-
tive HIV/AIDS control tool. There is also
some evidence that Schistosoma mansoni
infection could result in FGS, although at
a lower rate than S. haematobium infection
[28]; this also warrants further study,
particularly given that vaccines against
both S. haematobium and S. mansoni infection
are under development [2,29].
However, we also feel that the evidence
for FGS promoting HIV transmission is
sufficiently compelling that it would be
unethical to withhold mass treatment for
many years while awaiting the results of a
prospective study that follows school-age
girls as they become sexually active
women (and exposed to HIV). Van der
Werf et al. estimate there are 56 million
African school-age children with S. haema-
tobium infection [5], and presumably 28
million S. haematobium–infected school-age
girls. There are also another 14 million
preschool children and 7 million infected
Figure 1. Global distribution of S. haematobium Infection in Africa (As Well As S. japonicum and S. mekongi Infections in Asia) from the
World Health Organization. Reprinted with the permission of the WHO (from page 16 in [41], image WHO 92721).
doi:10.1371/journal.pntd.0000430.g001
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on the estimate that between 33% and
75% of women infected with S. haemato-
bium also exhibit signs and symptoms of
FGS [6], and taking the value of 54% as
the mean of these ranges, it follows that
approximately 19 million girls could
develop FGS over the next decade in
sub-Saharan Africa. With an appropriate
school-based praziquantel treatment re-
gime (annually in highly endemic areas), it
would be possible to prevent 16 million
cases of FGS in sub-Saharan Africa
through this approach. This assumes that
bi-annual praziquantel treatments can
reduce the prevalence of schistosomiasis
by 84% as shown previously in Burkina
Faso [21]. Although outside of South
Africa there are not well-established inci-
dence figures for HIV/AIDS in the
region, the Joint United Nations Pro-
gramme on HIV/AIDS (UNAIDS) re-
ports that 1.9 million new cases of HIV/
AIDS occurred in sub-Saharan Africa in
2007 [30], representing 0.25% of the total
population of 770 million in the region
[31]. By extrapolation we can estimate
that among a cohort of 16 million women
with FGS having a 3-fold increased risk of
HIV/AIDS (representing 0.75% of this
population), we could potentially prevent
up to 120,000 new cases of HIV/AIDS
through regular praziquantel treatments in
the next decade. Almost certainly, this
figure is a conservative estimate. In
addition, schistosomiasis is known to cause
Figure 2. Global Distribution of HIV/AIDS in Africa, Showing the HIV Prevalence (%) in Adults (15–49) in Africa, 2007. Reprinted with
the permission of UNAIDS (from page 39 in [30], Figure 2.8).
doi:10.1371/journal.pntd.0000430.g002
Table 1. School-Age and Preschool Children with S. haematobium Infection and FGS (Based on Data in [4,20,28]).
Preschool Children
Infected with S.
haematobium
School-Age
Children
Infected with
S. haematobium
Preschool and
School-Age
Children (and
Girls) with S.
haematobium
Preschool and
School-Age Girls
That Will Develop
FGS (Calculated
at a Rate of 54%)
over the Next
Decade
Conservative
Estimate of Cases
of FGS That Could
Be Prevented with
a Single Round of
Praziquantel
(Based on a
Reduction Rate
of 84%
Prevalence [20])
Costs of Annual
Treatment of 70
Million Preschool
and School-Age
Children Infected
with S. haematobium
(at a Cost of $0.32
per Child Based
on [28])
Costs of
Bi-Annual
Treatment
For 10 Years
14 million children 56 million children 70 million children and
35 million girls
19 million girls 16 million girls $22.4 million $112 million
doi:10.1371/journal.pntd.0000430.t001
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immunological activity in sperm (including
increased leukocytes and elevated cytokine
levels), decreasing after treatment [32,33].
For anatomical reasons, male genital
schistosomiasis does not appear to make
men more susceptible to HIV/AIDS.
However, dually infected men have been
hypothesized to increase the risk of HIV/
AIDS transmission to women through
higher HIV viral loads in seminal ejaculate
[33–35]. The viral loads in semen of
schistosomiasis-infected males has not yet
been investigated.
MDA of praziquantel is both low cost
and cost efficient. The SCI has determined
that even considering all of the delivery
costs, the mass treatment program of
school-age children in Burkina Faso was
conducted for only $0.32 per child [36].
Therefore, 70 million children infected
with S. haematobium could be treated for
$22 million, which, if repeated bi-annually
for 10 years, would cost approximately
$112 million (Table 1). By comparison,
PEPFAR (the US President’s Emergency
Plan for AIDS Relief) is projected to spend
$18.8 billion over the next 5 years (repre-
senting the largest international health
initiative ever devoted to a single disease),
including $1.34 billion annually in support
of treatment programs and $601 million
annually in support of treatment strategies
[37]. Therefore, periodic praziquantel ad-
ministration would represent a very small
add-on cost to the PEPFAR budget, and
yet would have the dual benefits of making
dramaticimprovementsinthe reproductive
health of women living in rural Africa,
likely reducing HIV/AIDS transmission.
Shown in Table 2 are the prevalence rates
of both HIV/AIDS and schistosomiasis in
the 15 countries where PEPFAR operates.
At the minimum, we strongly advocate for
the introduction of low-cost praziquantel
MDA in the PEPFAR countries of Mo-
zambique, Tanzania, and Zambia by using
PEPFAR funds in support of SCI activities
through a Global Network for NTDs [38–
40]. This represents a $0.32 solution that
could have enormous benefits for young
African women and a huge potential
beneficial impact on Africa’s AIDS epi-
demic.
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